Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis
Authors' conclusion
We found that mandatory switching policies were much more effective than new starting policies for increasing the use of biosimilar medications.
Study context
- Population
- British Columbia (BC) residents ≥18 years with RA, AS, PsA and/or plaque psoriasis with public drug coverage, January 2013 to November 20205,884 taking infliximab and etanercept
- Participants
- 208,984 residents
- Comparison
- Biosimilar uptake and spending after new start policy vs after switching policy
- Outcome
- Change in proportion spent on and prescriptions dispensed of biosimilar infliximab and etanercept out of the total per agent after new start and switching policies
Methodological detailsadministrative claims data
- Administrative claims data
Main finding
As reported in the abstract
- After new start policy: increase in proportion of dispensed biosimilar etanercept prescriptions per month
- 0.65% (95% CI 0.44, 0.85)
- After new start policy: trend in proportion of total spending on biosimilar etanercept
- 0.51% (95% CI 0.28, 0.73)
- After switching policy: sustained increase in proportion of dispensed biosimilar etanercept prescriptions
- 76.98% (95% CI 75.56, 78.41)
- After switching policy: sustained increase in proportion of dispensed biosimilar infliximab prescriptions
- 58.43% (95% CI 52.11, 64.75)
- After switching policy: persistent increase in monthly spending on biosimilar etanercept
- 78.22% (95% CI 76.65, 79.79)
- After switching policy: persistent increase in monthly spending on biosimilar infliximab
- 71.23% (95% CI 66.82, 75.65)
Original publication
Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis. Arthritis Care Res (Hoboken). Published 4 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →